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Abstract
Introduction: The purpose of our study was to determine whether hypothermia has any effects on physiological
hemodynamic responses to epinephrine (Epi), and whether rewarming reverses these effects.
Methods: Sprague-Dawley rats were instrumented to measure mean arterial pressure (MAP), and left ventricular
(LV) pressure-volume changes were recorded by using a Millar pressure-volume conductance catheter. Core
temperature was reduced from 37°C to 28°C and returned to 37°C by using both internal and external heat
exchangers. Two groups of rats were infused with either saline (n = 7), or Epi 0.125 μg/min continuously (n = 7). At
33°C, 30°C, and 28°C, the Epi infusion was temporarily increased from 0.125 to 1.25 μg/min.
Results: Before cooling, Epi infusion in both groups resulted in a significant, dose-dependent increase in heart rate
(HR), stroke volume (SV), cardiac output (CO), LV dP/dtmax (maximum derivative of systolic pressure over time), but
only Epi infusion at 1.25 μg/min caused elevation of MAP. During cooling to 30°C, Epi infusion at 0.125 μg/min
caused a significant elevation of central hemodynamic variables, whereas MAP remained unchanged. In contrast,
Epi infusions at 1.25 μg/min caused a significant elevation of MAP during cooling to 28°C but no increases in
central hemodynamics. After rewarming, all hemodynamic variables returned to baseline in both groups, but only
the saline-treated animals displayed the prehypothermic hemodynamic dose responses to Epi infusions.
Conclusions: This study shows that hypothermia causes a change in the physiological hemodynamic response to
Epi, which is not reversed by rewarming.
Introduction
Guidelines for using inotropic drugs to support cardio-
vascular function at low core temperatures are not well
characterized. Such guidelines are essential for treating
patients in acute heart failure, as will be the case during
induced therapeutic hypothermia, as well as during
rewarming from accidental hypothermia. Detailed
knowledge of temperature-dependent changes in phar-
macodynamics and pharmacokinetics of such cardioac-
tive drugs is essential for establishing treatment
guidelines.
Over the last decade, induced hypothermia is being
increasingly used to reduce cerebral damage in patients
after resuscitation from sudden cardiac arrest [1,2].
However, after return of spontaneous circulation
(ROSC), these patients often have acute heart failure
and need inotropic cardiac support to resume adequate
circulatory function [1] after induction of hypothermia
in which the core temperature is deliberately lowered to
34°C - 32°C and maintained for 24 to 48 hours.
Rewarming shock is a clinically descriptive term that
refers to a pathophysiologic state of cardiovascular col-
lapse taking place during or after rewarming from acci-
dental hypothermia [3]. Rewarming shock is recognized
as a progressive reduction of cardiac output (CO) and a
sudden decrease in arterial blood pressure. To treat or
prevent rewarming shock, cardioactive inotropic drugs
are commonly necessary to elevate low CO.
Relatively few studies have explored the pharmacolo-
gic effects of epinephrine or norepinephrine treatment
during hypothermia. Studies on the effects of epinephr-
ine (Epi) used to convert hypothermic cardiac arrest to
ROSC during cardiopulmonary resuscitation (CPR) in
pigs show diverse effects. In clinical practice, it is recog-
nized that in the acutely failing heart postoperatively or
after resuscitations, only drugs such as Epi and NE
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provide positive inotropy and perfusion pressure. The
American Heart Association (AHA) recommends the
following algorithm for the use of Epi during hypother-
mia; at less than 30°C, i.v. epinephrine should not be
given, but at greater than 30°C, epinephrine should be
given, if indicated, but at longer than standard intervals
[4].
In our laboratory, we found that Epi, if given in doses
(1.25 μg/ml) that increased CO, without affecting vascu-
lar resistance during normothermia, gave rise to vaso-
constriction (increased a-adrenoceptor response) but
failed to elevate low CO (decreased b-adrenoceptor
response) when given during hypothermia [5,6]. Thus,
in an attempt to elevate CO during cooling to 28°C in
our experimental hypothermia model, the effects of two
different Epi doses, 0.125 or 1.25 μg/ml, which both
exert significant cardiovascular effects during nor-
mothermia, were tested during hypothermia.
Materials and methods
The investigation conformed to the Guide for Care and
Use of Laboratory Animals, published by the U.S.
National Institutes of Health (NIH Publication No. 85-
23, revised 1996) and was performed with the approval
of the local Institutional Animal Care and Use
Committee.
Sprague-Dawley rats (males, 250 to 300 g), were used
in the experiments. Anesthesia was induced by sodium
pentobarbital (60 mg/kg body weight, i.p.), followed by a
continuous infusion of 7.5 mg/kg/h through an i.v. line
in the right jugular vein extended to the right auricle.
The animals were monitored for any sign of discomfort
during hypothermia and rewarming, so that an addi-
tional anesthesia might be provided if necessary.
Core cooling and rewarming
Animals were cooled and rewarmed by circulating cold
or warm water (thermostated water bath type RTE-110;
Neslab Instruments, Newington, NH, USA), respectively,
through a U-shaped polyethylene tube placed in the
lower bowels. In addition, the double-layered operating
table made of hollow aluminum was circulated by water
from this bath. Core temperature was continuously
monitored by using a thermocouple wire, with which
the sensor tip was positioned in the lower one third of
the esophagus (Thermoalert TH-5; Columbus Instru-
ments, Columbus, OH, USA).
Hemodynamic measurements
A microtip (2F), P-V catheter (SPR-838, Millar Instru-
ments; Houston, TX, USA) was inserted into the right
carotid artery and advanced into the LV under pressure
control. In addition, a pressure transducer was con-
nected to a fluid-filled catheter (22 G) implanted in the
left femoral artery for recording mean arterial pressure
(MAP). LV pressure and volume and MAP signals were
digitized at 1 kHz, and by an ARIA P-V conductance
system (Millar Instruments) coupled to a PowerLab/4SP
A/D converter (AD Instruments, Mountain View, CA,
USA) and a PC. HR, maximal LV systolic pressure
(LVSP), LV end-diastolic pressure (LVEDP), maximal
slope of LV systolic pressure increment (LV dP/dtmax)
and diastolic pressure decrement (LV dp/dtmin), time
constant of LV pressure decay (τ), stroke volume (SV),
end-diastolic volume (EDV), cardiac output (CO), stroke
work (SW), and MAP were computed by using a cardiac
P-V analysis program (PVAN 3.2; Millar Instruments,
Houston, TX, USA).
Special modifications related to the use of conductance
measurement and adjustments for parallel volume
determination at low core temperatures
This topic was described in detail previously [7]. In
brief, the measured conductance must be corrected for
parallel conductance induced by the alternating current
passing through the blood into the surrounding LV wall
or interventricular septum. Parallel conductance is
usually measured by the saline bolus injection at the
end of experiment. However, difficulties were antici-
pated when applying this method to our experimental
protocol, which required measurements of left ventricu-
lar volume at the specific experimental temperature (37°
C, 33°C, 30°C, and 28°C). In light of temperature-depen-
dent changes in viscosity of blood, the bolus injection
performed at the end of experiment cannot represent
the true parallel conductance at the other experimental
temperatures. For this reason, parallel conductance was
not included in our whole-volume measurements.
For a more accurate assessment of the left ventricular
volume, the cuvette calibration method was used,
requiring insulator-type cuvettes of known diameter (2,
3, 4, 5, 6, and 7 mm) filled with heparin-treated blood.
The volume cuvette containing heparin-treated blood
was positioned on the inside of a thermo-controlled
water circulator so that the temperature of the blood
could be adjusted during the calibration. Considering
temperature-dependent viscosity of blood, the volumes
measured at our specific experimental temperature
should be corrected by using the cuvette-calibration
method. Slopes and y-intercepts obtained at these tem-
peratures were applied to the analysis software (PVAN)
to convert conductance units to true volume units (μl).
Experimental protocol
After surgery, the animals were allowed to rest for 60
minutes before the start of the experiment. Based on
results from a dose-finding group (n = 3), the animals
were divided into two groups: one intervention group (n
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= 7), which was continuously infused with Epi, 0.125 μg/
min, and intermittently infused with Epi, 1.25 μg/min, at
33°C, 30°C, and 28°C, and one control group (n = 7)
receiving equivalent volumes of saline during cooling to
28°C. Infusions were terminated at 28°C before rewarm-
ing was started.
In both groups, the cardiovascular effects of infusing
Epi 0.125 and Epi 1.25 μg/min were tested before cool-
ing as well as after rewarming was completed.
Statistical analyses
Results are presented as mean ± SEM. For within-group
comparisons, data were assessed with one-way ANOVA
for repeated measurements followed, if the F value was
greater than critical, by the Dunnett test. To evaluate
differences between groups, one-way ANOVA was used,
followed, if the F value was greater than critical, by the
Tukey test. Differences were considered significant at p
< 0.05.
Results
All animals survived cooling and rewarming. Except for
single ectopic ventricular beats, no episodes of other
arrhythmias occurred during cooling and rewarming.
Assessment of Epi dose response
During normothermia (n = 3) (Figure 1), positive car-
diac inotropic effects were measured when infusing Epi
at doses 0.125 to 1.25 μg/ml, whereas Epi 3.75 μg/ml
showed negative effects on cardiac function simulta-
neous with an increase in afterload. Similar dose-depen-
dent effects of Epi on cardiovascular responses have
been shown in a previous study in our laboratory [6].
Hemodynamic stability, up to 5 hours at 37°C, has
been documented in numerous studies using the present
intact rat model [5-7].
Baseline 37°C control values
No significant differences in baseline values were found
for any of the hemodynamic variables measured between
saline and Epi groups at 37°C (saline versus Epi group)
(Figures 2 and 3).
Epinephrine, 0.125 μg/min, versus saline control group
In response to the low-dose (0.125 μg/min) Epi infused
at 37°C, CO and SW increased significantly (P < 0.05)
when compared with saline-treated controls.
Epinephrine, 1.25 μg/min, versus saline control group
Treatment with a higher dose (1.25 μg/min) of Epi
infused at 37°C caused a significant (P < 0.05) increase
Figure 1 Dose-finding group (n = 3).
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in HR, SV, CO, SW, and LV dP/dtmax. MAP increased
significantly compared with both saline-treated controls
and those with the infusion of Epi 0.125, μg/min.
Hemodynamic responses to cooling/rewarming
Saline control group
In response to cooling, a significant (P < 0.05) decrease
was noted in HR and Tau (not shown) at temperatures
less than 33°C, whereas the other hemodynamic vari-
ables remained unchanged during cooling to 28°C and
rewarming in this group (Figures 2 and 3).
Epi, 0.125 μg/min, or Epi, 1.25 μg/min, versus saline control
At 33°C, infusion of Epi at 0.125 μg/min significantly (P
< 0.05) increased HR, whereas Epi infusion at 1.25 μg/
min did not. In contrast to Epi infusion at 1.25 μg/min,
Epi infusion at 0.125 μg/min induced a significant (P <
0.05) increase in LV dP/dtmax and CO, the latter most
likely due to the increase in HR at this temperature.
Left ventricular end-systolic pressure (LVESP) and SW
increased significantly (P < 0.05) in response to both
doses of Epi at 33°C.
During cooling to 30°C and 28°C, no differences were
observed in HR between groups, but the differences in
hemodynamic responses between the two doses of Epi
became manifest at 30°C, at which Epi infusion at 0.125
μg/min significantly (P < 0.05) increased SV and CO when
compared with both Epi infusion at 1.25 μg/min and saline
infusion. In response to Epi infusion at 0.125 μg/min, SV
tended to increase, but this change was not significant. At
30°C, CO was significantly (P < 0.05) lower during Epi
infusion at 1.25 μg/min than during Epi infusion at 0.125
μg/min. Further, Epi infusion at 1.25 μg/min increased LV
end-systolic pressure as well as LV end-systolic volume
(LVESV) to significantly (P < 0.05) higher levels than did
Epi 0.125 μg/min infusion, and this linear increase in
LVESV continued during cooling to 28°C.
At 28°C, Epi infusions did not increase SV or CO
when compared with the saline group. No change in LV
Figure 2 Heart rate (a), cardiac output (b), left ventricular stroke work (c), and mean arterial pressure (d) expressed as a consequence
of cooling to 28°C and rewarming in animals receiving saline infusion (n = 7), or continuous infusion of (0.125 μg/min), and
intermittent infusion of Epi (1.25 μg/min) during cooling to 28°C (n = 7). Before rewarming, infusions were terminated. Values are
expressed as mean ± SEM. +P < 0.05 compared with saline group, †P < 0.05 comparisons within Epi group at each temperature, and ‡P < 0.05
compared with prehypothermic value in saline group.
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end-diastolic volume was observed within groups or
between groups throughout the experiments, a finding
that indicates why SV did not increase in response to
the Epi 1.25 μg/min infusion. In contrast, the Epi 0.125
μg/min infusion maintained a low LV end-systolic
volume throughout cooling to 28°C (demonstrating the
positive cardiac inotropic effects of this low-dose Epi on
cardiac function at temperatures between 33°C and 30°
C). However, at 28°C, the positive inotropic effect of
Epi, 0.125 μg/min, to increase CO was no longer
present.
Compared with their prehypothermic control values,
no statistically significant changes were observed in any
of the hemodynamic variables in the two groups during
Figure 3 Stroke volume (e), left ventricular dP/dtmax (f), left ventricular end-systolic volume (g), left ventricular end-diastolic volume
(h), left ventricular end-systolic pressure (i), and left ventricular end-diastolic pressure expressed as a consequence of cooling to 28°C
and rewarming in animals receiving saline infusion (n = 7), or continuous infusion of Epi (0.125 μg/min), and intermittent infusion of
Epi (1.25 μg/min) (n = 7). Before rewarming, infusions were terminated. Values are expressed as mean ± SEM. +P < 0.05 compared with saline
group, and †P < 0.05 comparisons within Epi group at each temperature.
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rewarming. During rewarming from 28°C, HR increased
linearly and was not significantly lower than prehy-
pothermic control values after 33°C (Figure 2). Likewise,
Tau returned to within control values after 30°C
rewarming (not shown).
Posthypothermic responses to Epi
Whereas Epi infusion demonstrated a significant dose/
response effect on vascular and LV cardiac function
before cooling, this dose/response effect of Epi infusion
on LV cardiac function was lost after rewarming (Figure
4). However, in the saline group, the cardiovascular
response to Epi infusion was maintained after
rewarming.
Discussion
The present study showed that a low-dose Epi managed
to maintain positive inotropic effects on LV cardiac
Figure 4 Changes in cardiac output (CO), stroke volume (SV), or mean arterial pressure in response to Epi, 0.125 μg/min, or Epi, 1.25
μg/min, before cooling and after rewarming in the group receiving saline (a), or Epi (b) during cooling to 28°C. *P < 0.05 compared
with corresponding baseline value.
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function during cooling to 30°C, but these effects van-
ished during cooling to 28°C. Second, a higher dose
(×10) Epi did not increase SV or CO at these low tem-
peratures, but induced a significant increase in afterload.
Third, the prehypothermic dose-dependent increase in
LV function in response to both a low- and a high-dose
Epi was reproducible after rewarming in the saline con-
trol group after cooling and rewarming, but not so in
the Epi-treated group.
The results of the present study showing a lack of car-
diac inotropic effects, combined with potentiating vascular
vasoconstriction at a higher-dose Epi during cooling to 28°
C, are in accordance with results previously reported by
others [8,9]. However, new information in the present
study is that a low-dose Epi exerts positive inotropic
effects on cardiac function without affecting afterload dur-
ing cooling to 30°C, a finding of importance for induced
hypothermia, as applied to reduce cerebral damage in
patients after resuscitation from sudden cardiac arrest.
Further, the lack of cardiac effects of Epi, irrespective of
dose, at temperatures below 30°C is of importance for
resuscitation from accidental hypothermia.
In mammals, epinephrine is the prominent catechola-
mine affecting cardiac contractility, acting through sti-
mulation via sarcolemmal b-adrenoceptors. In the
myocyte, Epi stimulates b-adrenoceptors, causing phos-
phorylation of the sarcolemmal L-type Ca2+ channel via
cyclic AMP and protein kinase A pathways. This phos-
phorylation increases the open probability of the chan-
nel [10], allowing for greater trans-sarcolemmal Ca2+
influx with each depolarization and producing, in part,
the positive inotropic effect of Epi. Farrell et al. [11]
reported increased adrenergic (Epi) sensitivity in fish
cardiomyocytes during acute cooling by showing that
sarcolemmal Ca2+ flux through the L-type Ca2+ channel
(I(Ca2+)) was significantly more sensitive to adrenergic
stimulation during cooling. Thus, although adrenergic
stimulation may affect the relative importance of SR Ca2
+ release in E-C coupling, temperature-induced modula-
tion of b-adrenoceptors may alter the efficacy of adre-
nergic effects. If cardiomyocytes from fish acclimatized
at 14°C were exposed to 7°C, a significant decrease in I
(Ca2+) was measured, but if Epi were added, I(Ca2+)
increased by a factor of 7.2, indicating a significant
increase in adrenergic sensitivity in response to cooling
[12]. As already mentioned, we found in our laboratory
that Epi, when given during normothermia in doses that
increased CO without affecting vascular resistance, gave
rise to vasoconstriction (increased a-adrenoceptor
response), but failed to elevate low CO (decreased b-
adrenoceptor response) when given during hypothermia
[6]. This finding also fit the idea that cooling may
induce a transition from b- to a-adrenoceptor
properties, as suggested in a study using isolated rat
atria [13]. As a result, Epi may not be an ideal inotropic
agent for enhancing CO at low core temperature, but
based on observations in the present study, the Epi dose
applied during hypothermia must be significantly lower
than doses normally used at 37°C core temperature.
Further, studies on the effects of Epi used to convert
hypothermic cardiac arrest to ROSC during CPR in pigs
show diverse effects. These studies all show that Epi will
increase coronary blood pressure (CPP) below 30°C,
which may be seen as a sign of adequate vascular
response to Epi at low core temperatures, but cardiac
effects (ROSC) are not conclusive [14-17].
Experimental data from Chernow [18] show that the
sympathetic nervous system could be “switched off” at a
threshold temperature about 29°C, and hypotensive
patients with temperatures below this may benefit from
infusions of exogenous catecholamines. In support of
this notion, a study on human skin artery responses to
tissue cooling showed an increased sensitivity in both
a1- and a2-adrenoreceptors to norepinephrine at 24°C
[19]. In addition, if CO could be elevated pharmacologi-
cally, rewarming by any means would become more effi-
cient [20]. Danzl and Pozos [21] recommend infusion of
low doses of catecholamines in patients who have lower
blood pressure than would be expected for that degree
of hypothermia and who are not responding to crystal-
loids and rewarming. However, in the present experi-
ment, we observed that in animals having received Epi
during cooling, the physiologic responses to Epi had
vanished after rewarming. This finding indicates that the
combined impact of hypothermia and adrenergic stimu-
lation has serious impact on b-adrenoceptor function
after normothermia is reestablished. Taken together, the
use of cardioactive drugs during hypothermic conditions
remains quite contradictory. Therefore, pharmacologic
treatment applied during the two clinically challenging
modalities outlined, induced and accidental hypother-
mia, call on written treatment protocols or guidelines
which are so far largely missing or at least not properly
updated. More research is needed to explore tempera-
ture-dependent changes in pharmacodynamics and
pharmacokinetics of cardioactive drugs to write these
guidelines.
Conclusions
Results from the present study show that a low-dose
Epi, in essential contrast to a high-dose Epi, exerts posi-
tive inotropic effects during cooling to 30°C. Because of
significant hypothermia-induced alterations of cardiac as
well as vascular adrenoceptor sensitivity, the use of car-
dioactive agents not affecting these receptor systems is
advised during hypothermic conditions.
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Key messages
• Dose-dependent physiologic responses to epinephr-
ine (Epi) are altered by hypothermia.
• A low-dose Epi may have positive inotropic cardiac
effects during cooling to 30°C.
• A high-dose Epi will elevate cardiac afterload sub-
stantially but leave cardiac inotropy unchanged.
• At less than 30°C, physiologic inotropic cardiac
responses to epinephrine (Epi) are not present.
• If Epi is administered during hypothermia, dose-
dependent physiologic responses to Epi are altered
after rewarming.
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